June 17, 2024


Imagination at work

Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Future Pharma PLC (Goal:DEST) (Future Pharma PLC (Goal:DEST)) is a medical stage, innovative biotechnology firm targeted on the enhancement of novel medications that can protect against life-threatening infections. The firm’s pipeline has novel microbiome-centered biotherapeutics and XF drug medical assets together with NTCD-M3, a Section 3 ready remedy for the prevention of C. difficile infection (CDI) recurrence which is the foremost cause of hospital acquired infections in the US. Destiny’s pipeline also features XF-73 nasal gel, which has recently finished a good Section 2b medical trial focusing on the prevention of write-up-surgical staphylococcal hospital infections together with MRSA. The firm is also co-creating SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.